US Stock MarketDetailed Quotes

AMLX Amylyx Pharmaceuticals

Watchlist
  • 3.720
  • +0.130+3.62%
Close Feb 14 16:00 ET
  • 3.720
  • 0.0000.00%
Post 20:01 ET
318.76MMarket Cap-0.97P/E (TTM)

About Amylyx Pharmaceuticals Company

Amylyx Pharmaceuticals, Inc. is a commercial-stage biotechnology company, which engages in the provision of therapies for neurodegenerative diseases and amyotrophic lateral sclerosis (ALS). Its commercial product is Relyvrio, also known as Albrioza in Canada. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.

Company Profile

SymbolAMLX
Company NameAmylyx Pharmaceuticals
Listing DateJan 7, 2022
Issue Price19.00
Founded2013
MarketNASDAQ
Employees384
Fiscal Year Ends12-31
Address43 Thorndike Street
CityCambridge
ProvinceMassachusetts
CountryUnited States of America
Zip Code02141
Phone1-617-682-0917
Websitehttp://www.amylyx.com

Company Executives

  • Name
  • Position
  • Salary
  • Joshua Cohen
  • Co-Chief Executive Officer and Director
  • 7.42M
  • Justin Klee
  • Co-Chief Executive Officer and Director
  • 7.42M
  • Gina M. Mazzariello
  • Chief Legal Officer and General Counsel
  • 3.01M
  • Dr. Camille L. Bedrosian,M.D.
  • Chief Medical Officer
  • 2.37M
  • James M. Frates
  • Chief Financial Officer and Principal Accounting Officer
  • 3.51M
  • Dr. George Mclean Milne, Jr,PhD
  • Chairman of the Board
  • 385.07K
  • Dr. Bernhardt G. Zeiher, F.A.C.P.,F.C.C.P.,M.D.
  • Director
  • --
  • Paul Fonteyne, M.S.
  • Independent Director
  • 342.12K
  • Karen Firestone
  • Independent Director
  • 681.15K
  • Daphne E. Quimi
  • Independent Director
  • 348.59K

Trending Stocks

Top Gaining Chinese Stocks Top Gaining Chinese Stocks
No. Symbol % Chg
XINGANJIANG
873167
+30.00%
INNOVATIVE DATA
835305
+29.98%
CHENGUANG MEDICAL
430300
+29.96%
4
Hangzhou Gaoxin Materials Technology
300478
+20.04%
5
Beijing Philisense Technology
300287
+20.03%
Log In for the Full List
Unlock Now
Investment Course
Top 5 Industries for Stock Trading under Trump's Second Term
Stocks & Industries to Watch Under Trump's Second Presidency
With mooomoo, find out which stocks and industries may benefit from Trump's second presidency, based on his first administration's track record.
Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Discussing
Many institutions are bullish! What's ahead for Chinese stocks in 2025?
Recently, institutions such as Goldman Sachs, Morgan Stanley, and Appaloosa LP have spoken positively about Chinese assets. 🎙️Discussion: 1 Show More
China's asset revaluation sparks debate: What are mooers buying?